株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

HLAタイピングの世界市場:技術 (PCR・NGS・サンガーシーケンシング)、製品 (装置・試薬)、用途 (癌研究・感染症&非感染症・輸血療法)、エンドユーザー (2025年までの予測)

HLA Typing Market by Technology (PCR, NGS, Sanger Sequencing), Product (Instrument, Reagent), Application (Cancer research, infectious & Non infectious diseases, Transfusion therapy), End User (Hospital, Academia and Research) - Global Forecast to 2025

発行 MarketsandMarkets 商品コード 928718
出版日 ページ情報 英文 186 Pages
即納可能
価格
本日の銀行送金レート: 1USD=109.96円で換算しております。
HLAタイピングの世界市場:技術 (PCR・NGS・サンガーシーケンシング)、製品 (装置・試薬)、用途 (癌研究・感染症&非感染症・輸血療法)、エンドユーザー (2025年までの予測) HLA Typing Market by Technology (PCR, NGS, Sanger Sequencing), Product (Instrument, Reagent), Application (Cancer research, infectious & Non infectious diseases, Transfusion therapy), End User (Hospital, Academia and Research) - Global Forecast to 2025
出版日: 2020年03月12日 ページ情報: 英文 186 Pages
概要

世界のHLAタイピング市場規模は、2020年の13億米ドルから、2025年までに17億米ドルに達すると予測されており、予測期間中のCAGRは5.9%が見込まれています。HLAタイピング市場の成長は、HLAタイピング処置数の増加、HLAタイピングの分野における技術進歩、および研究資金の増加などによって促進されています。製品・サービス別では、試薬・消耗品セグメントが2019年において最大の市場シェアを構成しました。これは、HLAタイピングにおける分子アッセイ技術の応用分野の拡大、臓器移植中の効果的かつ早期の患者プロファイリングを重視する患者の増加、調査研究における分子診断技術の導入拡大、および主要市場にわたる標的処置数の増加などに起因しています。

当レポートでは、世界のHLAタイピング市場について調査分析し、各セグメント・地域別の市場分析と予測、市場発展への影響要因、競合環境、および主要企業などについて、体系的な情報を提供しています。

928718_4.3 HLA TYPING MARKET, BY TECHNOLOGY_FIGURE 13

第1章 イントロダクション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 重要考察

  • HLAタイピング市場:市場概要
  • 世界市場の分析:製品・サービス別
  • HLAタイピング市場:技術別
  • HLAタイピング市場:用途別
  • HLAタイピング市場:エンドユーザー別
  • HLAタイピング市場の地域スナップショット

第5章 市場概要

  • イントロダクション
  • 市場ダイナミクス
    • 促進要因
    • 抑制要因
    • 市場機会
    • 課題

第6章 HLAタイピング市場:製品・サービス別

  • イントロダクション
  • 試薬・消耗品
  • 装置
  • ソフトウェア・サービス

第7章 HLAタイピング市場:技術別

  • イントロダクション
  • 分子アッセイ技術
  • 非分子アッセイ技術

第8章 HLAタイピング市場:用途別

  • イントロダクション
  • 診断用途
  • 研究用途

第9章 HLAタイピング市場:エンドユーザー別

  • イントロダクション
  • 民間サービスプロバイダー
  • 病院・移植センター
  • 研究ラボ・学術機関

第10章 HLAタイピング市場:地域別

  • イントロダクション
  • 北米
  • 欧州
  • アジア太平洋
  • ラテンアメリカ
  • 中東・アフリカ

第11章 競合情勢

  • 概要
  • 市場シェア分析
  • 競合シナリオ
  • 競合リーダーシップマッピング

第12章 企業プロファイル

  • THERMO FISHER SCIENTIFIC
  • QIAGEN
  • ILLUMINA
  • F. HOFFMAN-LA ROCHE LIMITED
  • BIO-RAD LABORATORIES
  • BECTON, DICKINSON AND COMPANY
  • TBG DIAGNOSTICS
  • 富士レビオ
  • タカラバイオ
  • CAREDX
  • OMIXON
  • IMMUCOR
  • GENOME DIAGNOSTICS
  • BIOFORTUNA
  • CREATIVE BIOLABS
  • その他の企業
    • BAG HEALTHCARE
    • HISTOGENETICS
    • PACIFIC BIOSCIENCES OF CALIFORNIA
    • BGI GENOMICS
    • KRISHGEN BIOSYSTEMS

第13章 付録

図表

LIST OF TABLES

  • TABLE 1: PUBLIC-PRIVATE INVESTMENTS AND RESEARCH GRANTS FOR THE DEVELOPMENT OF HLA TYPING PRODUCTS, 2015-2018
  • TABLE 2: COST OF ASSAYS FOR MAJOR NGS/PCR-BASED GENOMIC TESTS IN EUROPE (AS OF 2017)
  • TABLE 3: HLA TYPING MARKET, BY PRODUCT & SERVICE, 2017-2025 (USD MILLION)
  • TABLE 4: HLA TYPING MARKET FOR REAGENTS & CONSUMABLES, BY REGION, 2017-2025 (USD MILLION)
  • TABLE 5: HLA TYPING MARKET FOR INSTRUMENTS, BY REGION, 2017-2025 (USD MILLION)
  • TABLE 6: HLA TYPING MARKET FOR SOFTWARE & SERVICES, BY REGION, 2017-2025 (USD MILLION)
  • TABLE 7: HLA TYPING MARKET, BY TECHNOLOGY, 2017-2025 (USD MILLION)
  • TABLE 8: HLA TYPING MARKET FOR MOLECULAR ASSAY TECHNOLOGIES, BY TYPE, 2017-2025 (USD MILLION)
  • TABLE 9: HLA TYPING MARKET FOR MOLECULAR ASSAY TECHNOLOGIES, BY PRODUCT & SERVICE, 2017-2025 (USD MILLION)
  • TABLE 10: HLA TYPING MARKET FOR MOLECULAR ASSAY TECHNOLOGIES, BY APPLICATION, 2017-2025 (USD MILLION)
  • TABLE 11: HLA TYPING MARKET FOR MOLECULAR ASSAY TECHNOLOGIES, BY END USER, 2017-2025 (USD MILLION)
  • TABLE 12: HLA TYPING MARKET FOR MOLECULAR ASSAY TECHNOLOGIES, BY REGION, 2017-2025 (USD MILLION)
  • TABLE 13: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2017-2025 (USD MILLION)
  • TABLE 14: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY PRODUCT & SERVICE, 2017-2025 (USD MILLION)
  • TABLE 15: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY APPLICATION, 2017-2025 (USD MILLION)
  • TABLE 16: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY END USER, 2017-2025 (USD MILLION)
  • TABLE 17: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY REGION, 2017-2025 (USD MILLION)
  • TABLE 18: HLA TYPING MARKET FOR SEQUENCE-SPECIFIC PRIMER-PCR, BY REGION, 2017-2025 (USD MILLION)
  • TABLE 19: HLA TYPING MARKET FOR SEQUENCE-SPECIFIC OLIGONUCLEOTIDE-PCR, BY REGION, 2017-2025 (USD MILLION)
  • TABLE 20: HLA TYPING MARKET FOR REAL-TIME PCR, BY REGION, 2017-2025 (USD MILLION)
  • TABLE 21: HLA TYPING MARKET FOR OTHER PCR-BASED MOLECULAR ASSAYS, BY REGION, 2017-2025 (USD MILLION)
  • TABLE 22: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2017-2025 (USD MILLION)
  • TABLE 23: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY PRODUCT & SERVICE, 2017-2025 (USD MILLION)
  • TABLE 24: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY APPLICATION, 2017-2025 (USD MILLION)
  • TABLE 25: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY END USER, 2017-2025 (USD MILLION)
  • TABLE 26: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY REGION, 2017-2025 (USD MILLION)
  • TABLE 27: HLA TYPING MARKET FOR SANGER SEQUENCING, BY REGION, 2017-2025 (USD MILLION)
  • TABLE 28: HLA TYPING MARKET FOR NEXT-GENERATION SEQUENCING, BY REGION, 2017-2025 (USD MILLION)
  • TABLE 29: HLA TYPING MARKET FOR OTHER SEQUENCING-BASED MOLECULAR ASSAYS, BY REGION, 2017-2025 (USD MILLION)
  • TABLE 30: HLA TYPING MARKET FOR NON-MOLECULAR ASSAY TECHNOLOGIES, BY PRODUCT & SERVICE, 2017-2025 (USD MILLION)
  • TABLE 31: HLA TYPING MARKET FOR NON-MOLECULAR ASSAY TECHNOLOGIES, BY APPLICATION, 2017-2025 (USD MILLION)
  • TABLE 32: HLA TYPING MARKET FOR NON-MOLECULAR ASSAY TECHNOLOGIES, BY END USER, 2017-2025 (USD MILLION)
  • TABLE 33: HLA TYPING MARKET FOR NON-MOLECULAR ASSAY TECHNOLOGIES, BY REGION, 2017-2025 (USD MILLION)
  • TABLE 34: HLA TYPING MARKET, BY APPLICATION, 2017-2025 (USD MILLION)
  • TABLE 35: HLA TYPING MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2017-2025 (USD MILLION)
  • TABLE 36: HLA TYPING MARKET FOR DIAGNOSTIC APPLICATIONS, BY REGION, 2017-2025 (USD MILLION)
  • TABLE 37: HLA TYPING MARKET FOR DONOR-RECIPIENT CROSS-MATCHING, BY REGION, 2017-2025 (USD MILLION)
  • TABLE 38: HLA TYPING MARKET FOR INFECTIOUS DISEASE TESTING, BY REGION, 2017-2025 (USD MILLION)
  • TABLE 39: HLA TYPING MARKET FOR CANCER DIAGNOSIS & PREVENTION, BY REGION, 2017-2025 (USD MILLION)
  • TABLE 40: HLA TYPING MARKET FOR TRANSFUSION THERAPY, BY REGION, 2017-2025 (USD MILLION)
  • TABLE 41: HLA TYPING MARKET FOR OTHER DIAGNOSTIC APPLICATIONS, BY REGION, 2017-2025 (USD MILLION)
  • TABLE 42: HLA TYPING MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2017-2025 (USD MILLION)
  • TABLE 43: HLA TYPING MARKET, BY END USER, 2017-2025 (USD MILLION)
  • TABLE 44: HLA TYPING MARKET FOR COMMERCIAL SERVICE PROVIDERS, BY REGION, 2017-2025 (USD MILLION)
  • TABLE 45: HLA TYPING MARKET FOR HOSPITALS & TRANSPLANT CENTERS, BY REGION, 2017-2025 (USD MILLION)
  • TABLE 46: HLA TYPING MARKET FOR RESEARCH LABORATORIES & ACADEMIC INSTITUTES, BY REGION, 2017-2025 (USD MILLION)
  • TABLE 47: HLA TYPING MARKET, BY REGION, 2017-2025 (USD MILLION)
  • TABLE 48: NORTH AMERICA: HLA TYPING MARKET, BY COUNTRY, 2017-2025 (USD MILLION)
  • TABLE 49: NORTH AMERICA: HLA TYPING MARKET, BY TECHNOLOGY, 2017-2025 (USD MILLION)
  • TABLE 50: NORTH AMERICA: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2017-2025 (USD MILLION)
  • TABLE 51: NORTH AMERICA: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2017-2025 (USD MILLION)
  • TABLE 52: NORTH AMERICA: HLA TYPING MARKET, BY PRODUCT & SERVICE, 2017-2025 (USD MILLION)
  • TABLE 53: NORTH AMERICA: HLA TYPING MARKET, BY APPLICATION, 2017-2025 (USD MILLION)
  • TABLE 54: NORTH AMERICA: HLA TYPING MARKET, BY END USER, 2017-2025 (USD MILLION)
  • TABLE 55: SOLID-ORGAN TRANSPLANTATIONS PERFORMED IN THE US, BY TYPE, 2017-2018
  • TABLE 56: TARGET DISEASES INCIDENCE IN THE US, BY TYPE, 2018
  • TABLE 57: NEW CANCER CASES IN THE US, BY ORGAN, 2017
  • TABLE 58: US: HLA TYPING MARKET, BY TECHNOLOGY, 2017-2025 (USD MILLION)
  • TABLE 59: US: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2017-2025 (USD MILLION)
  • TABLE 60: US: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2017-2025 (USD MILLION)
  • TABLE 61: SOLID-ORGAN TRANSPLANTATIONS PERFORMED IN CANADA, BY TYPE, 2017-2018
  • TABLE 62: TARGET DISEASE INCIDENCE IN CANADA, 2017
  • TABLE 63: NEW CANCER CASES IN CANADA, BY ORGAN, 2018
  • TABLE 64: CANADA: HLA TYPING MARKET, BY TECHNOLOGY, 2017-2025 (USD MILLION)
  • TABLE 65: CANADA: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2017-2025 (USD MILLION)
  • TABLE 66: CANADA: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2017-2025 (USD MILLION)
  • TABLE 67: EUROPE: HLA TYPING MARKET, BY COUNTRY, 2017-2025 (USD MILLION)
  • TABLE 68: EUROPE: HLA TYPING MARKET, BY TECHNOLOGY, 2017-2025 (USD MILLION)
  • TABLE 69: EUROPE: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2017-2025 (USD MILLION)
  • TABLE 70: EUROPE: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2017-2025 (USD MILLION)
  • TABLE 71: EUROPE: HLA TYPING MARKET, BY PRODUCT & SERVICE, 2017-2025 (USD MILLION)
  • TABLE 72: EUROPE: HLA TYPING MARKET, BY APPLICATION, 2017-2025 (USD MILLION)
  • TABLE 73: EUROPE: HLA TYPING MARKET, BY END USER, 2017-2025 (USD MILLION)
  • TABLE 74: SOLID-ORGAN TRANSPLANTATIONS PERFORMED IN GERMANY, BY TYPE, 2017-2018
  • TABLE 75: TARGET DISEASE INCIDENCE IN GERMANY, 2017
  • TABLE 76: NEW CANCER CASES IN GERMANY, BY ORGAN, 2017
  • TABLE 77: GERMANY: HLA TYPING MARKET, BY TECHNOLOGY, 2017-2025 (USD MILLION)
  • TABLE 78: GERMANY: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2017-2025 (USD MILLION)
  • TABLE 79: GERMANY: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2017-2025 (USD MILLION)
  • TABLE 80: SOLID-ORGAN TRANSPLANTATIONS PERFORMED IN THE UK, BY TYPE, 2017-2018
  • TABLE 81: TARGET DISEASE INCIDENCE IN THE UK, 2017
  • TABLE 82: NEW CANCER CASES IN THE UK, BY ORGAN, 2018
  • TABLE 83: UK: HLA TYPING MARKET, BY TECHNOLOGY, 2017-2025 (USD MILLION)
  • TABLE 84: UK: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2017-2025 (USD MILLION)
  • TABLE 85: UK: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2017-2025 (USD MILLION)
  • TABLE 86: SOLID-ORGAN TRANSPLANTATIONS PERFORMED IN FRANCE, BY TYPE, 2017-2018
  • TABLE 87: NEW CANCER CASES IN FRANCE, BY ORGAN, 2018
  • TABLE 88: FRANCE: HLA TYPING MARKET, BY TECHNOLOGY, 2017-2025 (USD MILLION)
  • TABLE 89: FRANCE: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2017-2025 (USD MILLION)
  • TABLE 90: FRANCE: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2017-2025 (USD MILLION)
  • TABLE 91: ITALY: HLA TYPING MARKET, BY TECHNOLOGY, 2017-2025 (USD MILLION)
  • TABLE 92: ITALY: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2017-2025 (USD MILLION)
  • TABLE 93: ITALY: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2017-2025 (USD MILLION)
  • TABLE 94: SPAIN: HLA TYPING MARKET, BY TECHNOLOGY, 2017-2025 (USD MILLION)
  • TABLE 95: SPAIN: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2017-2025 (USD MILLION)
  • TABLE 96: SPAIN: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2017-2025 (USD MILLION)
  • TABLE 97: ROE: HLA TYPING MARKET, BY TECHNOLOGY, 2017-2025 (USD MILLION)
  • TABLE 98: ROE: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2017-2025 (USD MILLION)
  • TABLE 99: ROE: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2017-2025 (USD MILLION)
  • TABLE 100: ASIA PACIFIC: HLA TYPING MARKET, BY COUNTRY, 2017-2025 (USD MILLION)
  • TABLE 101: ASIA PACIFIC: HLA TYPING MARKET, BY TECHNOLOGY, 2017-2025 (USD MILLION)
  • TABLE 102: ASIA PACIFIC: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2017-2025 (USD MILLION)
  • TABLE 103: ASIA PACIFIC: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2017-2025 (USD MILLION)
  • TABLE 104: ASIA PACIFIC: HLA TYPING MARKET, BY PRODUCT & SERVICE, 2017-2025 (USD MILLION)
  • TABLE 105: ASIA PACIFIC: HLA TYPING MARKET, BY APPLICATION, 2017-2025 (USD MILLION)
  • TABLE 106: ASIA PACIFIC: HLA TYPING MARKET, BY END USER, 2017-2025 (USD MILLION)
  • TABLE 107: SOLID-ORGAN TRANSPLANTATIONS PERFORMED IN CHINA, BY TYPE, 2017-2018
  • TABLE 108: NEW CANCER CASES IN CHINA, BY ORGAN, 2018
  • TABLE 109: CHINA: HLA TYPING MARKET, BY TECHNOLOGY, 2017-2025 (USD MILLION)
  • TABLE 110: CHINA: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2017-2025 (USD MILLION)
  • TABLE 111: CHINA: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2017-2025 (USD MILLION)
  • TABLE 112: SOLID-ORGAN TRANSPLANTATIONS PERFORMED IN INDIA, BY TYPE, 2017-2018
  • TABLE 113: NEW CANCER CASES IN INDIA, BY ORGAN, 2018
  • TABLE 114: INDIA: HLA TYPING MARKET, BY TECHNOLOGY, 2017-2025 (USD MILLION)
  • TABLE 115: INDIA: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2017-2025 (USD MILLION)
  • TABLE 116: INDIA: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2017-2025 (USD MILLION)
  • TABLE 117: SOLID-ORGAN TRANSPLANTATIONS PERFORMED IN JAPAN, BY TYPE, 2017-2018
  • TABLE 118: NEW CANCER CASES IN JAPAN, BY ORGAN, 2018
  • TABLE 119: JAPAN: HLA TYPING MARKET, BY TECHNOLOGY, 2017-2025 (USD MILLION)
  • TABLE 120: JAPAN: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2017-2025 (USD MILLION)
  • TABLE 121: JAPAN: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2017-2025 (USD MILLION)
  • TABLE 122: SOLID-ORGAN TRANSPLANTATIONS PERFORMED IN AUSTRALIA, BY TYPE, 2017-2018
  • TABLE 123: NEW CANCER CASES IN AUSTRALIA, BY ORGAN, 2018
  • TABLE 124: AUSTRALIA: HLA TYPING MARKET, BY TECHNOLOGY, 2017-2025 (USD MILLION)
  • TABLE 125: AUSTRALIA: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2017-2025 (USD MILLION)
  • TABLE 126: AUSTRALIA: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2017-2025 (USD MILLION)
  • TABLE 127: SOUTH KOREA: HLA TYPING MARKET, BY TECHNOLOGY, 2017-2025 (USD MILLION)
  • TABLE 128: SOUTH KOREA: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2017-2025 (USD MILLION)
  • TABLE 129: SOUTH KOREA: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2017-2025 (USD MILLION)
  • TABLE 130: ROAPAC: HLA TYPING MARKET, BY TECHNOLOGY, 2017-2025 (USD MILLION)
  • TABLE 131: ROAPAC: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2017-2025 (USD MILLION)
  • TABLE 132: ROAPAC: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2017-2025 (USD MILLION)
  • TABLE 133: LATAM: HLA TYPING MARKET, BY COUNTRY, 2017-2025 (USD MILLION)
  • TABLE 134: LATAM: HLA TYPING MARKET, BY TECHNOLOGY, 2017-2025 (USD MILLION)
  • TABLE 135: LATAM: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2017-2025 (USD MILLION)
  • TABLE 136: LATAM: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2017-2025 (USD MILLION)
  • TABLE 137: LATAM: HLA TYPING MARKET, BY PRODUCT & SERVICE, 2017-2025 (USD MILLION)
  • TABLE 138: LATAM: HLA TYPING MARKET, BY APPLICATION, 2017-2025 (USD MILLION)
  • TABLE 139: LATAM: HLA TYPING MARKET, BY END USER, 2017-2025 (USD MILLION)
  • TABLE 140: SOLID-ORGAN TRANSPLANTATIONS PERFORMED IN BRAZIL, BY TYPE, 2017-2018
  • TABLE 141: NEW CANCER CASES IN BRAZIL, BY ORGAN, 2018
  • TABLE 142: BRAZIL: HLA TYPING MARKET, BY TECHNOLOGY, 2017-2025 (USD MILLION)
  • TABLE 143: BRAZIL: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2017-2025 (USD MILLION)
  • TABLE 144: BRAZIL: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2017-2025 (USD MILLION)
  • TABLE 145: SOLID-ORGAN TRANSPLANTATIONS PERFORMED IN MEXICO, BY TYPE, 2017-2018
  • TABLE 146: NEW CANCER CASES IN MEXICO, BY ORGAN, 2018
  • TABLE 147: MEXICO: HLA TYPING MARKET, BY TECHNOLOGY, 2017-2025 (USD MILLION)
  • TABLE 148: MEXICO: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2017-2025 (USD MILLION)
  • TABLE 149: MEXICO: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2017-2025 (USD MILLION)
  • TABLE 150: ROLATAM: HLA TYPING MARKET, BY TECHNOLOGY, 2017-2025 (USD MILLION)
  • TABLE 151: ROLATAM: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2017-2025 (USD MILLION)
  • TABLE 152: ROLATAM: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2017-2025 (USD MILLION)
  • TABLE 153: MEA: HLA TYPING MARKET, BY TECHNOLOGY, 2017-2025 (USD MILLION)
  • TABLE 154: MEA: HLA TYPING MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2017-2025 (USD MILLION)
  • TABLE 155: MEA: HLA TYPING MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2017-2025 (USD MILLION)
  • TABLE 156: MEA: HLA TYPING MARKET, BY PRODUCT & SERVICE, 2017-2025 (USD MILLION)
  • TABLE 157: MEA: HLA TYPING MARKET, BY APPLICATION, 2017-2025 (USD MILLION)
  • TABLE 158: MEA: HLA TYPING MARKET, BY END USER, 2017-2025 (USD MILLION)

LIST OF FIGURES

  • FIGURE 1: RESEARCH DESIGN
  • FIGURE 2: BREAKDOWN OF PRIMARIES: GLOBAL HLA TYPING MARKET
  • FIGURE 3: RESEARCH METHODOLOGY: HYPOTHESIS BUILDING
  • FIGURE 4: MARKET SIZE ESTIMATION: HLA TYPING MARKET
  • FIGURE 5: DATA TRIANGULATION METHODOLOGY
  • FIGURE 6: HLA TYPING MARKET SHARE, BY PRODUCT, 2019 VS. 2025 (USD MILLION)
  • FIGURE 7: HLA TYPING MARKET SHARE, BY APPLICATION, 2019 VS. 2025
  • FIGURE 8: HLA TYPING MARKET, BY TECHNOLOGY, 2019-2025 (USD MILLION)
  • FIGURE 9: HLA TYPING MARKET, BY END USER
  • FIGURE 10: HLA TYPING MARKET, BY REGION: GEOGRAPHICAL SNAPSHOT
  • FIGURE 11: INCREASING NUMBER OF ORGAN TRANSPLANTATION PROCEDURES ACROSS THE GLOBE IS SUPPORTING THE GROWTH OF THE MARKET
  • FIGURE 12: REAGENTS & CONSUMABLES HELD THE LARGEST SHARE OF THE MARKET
  • FIGURE 13: MOLECULAR ASSAY TECHNOLOGIES SEGMENT TO HOLD LARGEST SHARE OF THE GLOBAL MARKET
  • FIGURE 14: DIAGNOSTIC APPLICATIONS HOLD THE MAJOR SHARE OF THE MARKET, BY APPLICATION
  • FIGURE 15: COMMERCIAL SERVICE PROVIDERS SEGMENT WILL REGISTER THE HIGHEST CAGR
  • FIGURE 16: CHINA TO REGISTER THE HIGHEST CAGR DURING THE FORECAST PERIOD
  • FIGURE 17: HLA TYPING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 18: NORTH AMERICA: HLA TYPING MARKET SNAPSHOT
  • FIGURE 19: ASIA PACIFIC: HLA TYPING MARKET SNAPSHOT
  • FIGURE 20: PRODUCT LAUNCHES AND ENHANCEMENTS WERE THE KEY GROWTH STRATEGIES ADOPTED BY MARKET PLAYERS FROM 2016 TO 2019
  • FIGURE 21: THERMO FISHER SCIENTIFIC DOMINATES THE GLOBAL HLA TYPING MARKET, AS OF 2019
  • FIGURE 22: HLA TYPING MARKET (GLOBAL): COMPETITIVE LEADERSHIP MAPPING, 2019
  • FIGURE 23: THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT (2018)
  • FIGURE 24: QIAGEN: COMPANY SNAPSHOT (2018)
  • FIGURE 25: ILLUMINA: COMPANY SNAPSHOT (2019)
  • FIGURE 26: F. HOFFMAN-LA ROCHE LIMITED: COMPANY SNAPSHOT (2018)
  • FIGURE 27: BIO-RAD LABORATORIES: COMPANY SNAPSHOT (2018)
  • FIGURE 28: BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2018)
  • FIGURE 29: TBG DIAGNOSTICS LIMITED: COMPANY SNAPSHOT (2018)
  • FIGURE 30: FUJIREBIO: COMPANY SNAPSHOT (2016)
  • FIGURE 31: TAKARA: COMPANY SNAPSHOT (2019)
  • FIGURE 32: CAREDX: COMPANY SNAPSHOT (2018)
  • FIGURE 33: IMMUCOR: COMPANY SNAPSHOT (2016)
目次
Product Code: MD 7576

"The HLA typing market is projected to grow at a CAGR of 5.9% during the forecast period."

The global HLA typing market is projected to reach USD 1.7 billion by 2025 from USD 1.3 billion in 2020, at a CAGR of 5.9%. Growth in the HLA typing market is mainly driven by factors such as the increasing number of HLA typing procedures conducted, technological advancements in the field of HLA typing, and increasing funding for research.

"Reagents & consumables accounted for the largest market share in 2019."

Based on product and service, the HLA typing market is segmented into reagents & consumables, instruments, and software & services. The reagents & consumables segment accounted for the largest share of the HLA typing market in 2019. This can be attributed to the growing application horizons of molecular assay techniques in HLA typing, increasing patient emphasis on effective and early patient profiling during organ transplantation, the growing adoption of molecular diagnostic techniques in research studies, and the rising number of target procedures across major markets.

"The molecular assay technologies segment accounted for the largest share of the HLA typing market in 2019."

On the basis of technology, the HLA typing market is segmented into molecular and non-molecular assay technologies. The molecular assay technologies segment accounted for the largest share of the HLA typing market in 2019. The growth of this segment is attributed to their benefits over non-molecular assays, such as low turnaround times, high procedural efficacy, multi-sample study capabilities, and real-time sample analysis.

"The diagnostic applications segment accounted for the largest share of the HLA typing market in 2019."

Based on application, the HLA typing market is segmented into diagnostic and research applications. The diagnostic applications segment dominates the HLA typing market. This is attributed to technological advancements in molecular assay techniques, the increasing adoption of molecular assay procedures for pathogen encounter detection and histocompatibility cross-matching, and the growing incidence of chronic and infectious diseases.

"The commercial service providers segment accounted for the largest share of the HLA typing market in 2019."

The HLA typing market, by end user, is segmented into commercial service providers, hospitals & surgical centers, and research laboratories & academic institutes. In 2019, the commercial service providers segment accounted for the largest share of the HLA typing market due to the ongoing rapid modernization and adoption of automation in HLA typing, growing outsourcing of R&D activities to said providers, and the increasing consolidation of diagnostic laboratories.

"North America accounted for the largest share of the global HLA typing market in 2019."

The HLA typing market is segmented into five major regions, namely, North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America accounted for the largest share of the global HLA typing market in 2019. This is majorly attributed to the high adoption of advanced diagnostic technologies, increasing prevalence of target diseases in the US and Canada, and technological advancements. The rising geriatric population and growing funding and support for research are other major factors driving the growth of this regional segment.

Breakdown of supply-side primary interviews:

  • By Company Type: Tier 1 (42%), Tier 2 (28%), and Tier 3 (30%)
  • By Designation: C-level (76%), Director-level (10%), and Others (14%)
  • By Region: North America (40%), Europe (30%), APAC (22%), LATAM (6%), and the MEA (2%)

The major players operating in the HLA typing market include: Thermo Fisher Scientific Inc. (US), Bio-Rad Laboratories, Inc. (US), F. Hoffman-La Roche Ltd. (Switzerland), QIAGEN N.V. (Netherlands), Illumina, Inc. (US), Immucor, Inc. (US), CareDx (US), Becton, Dickinson and Company (US), and Hologic (US).

Research Coverage:

This report studies the HLA typing market based on product and service, technology, applications, end user, and region. The report also studies the major factors affecting market growth, such as drivers, restraints, opportunities, and challenges. In addition, it analyzes the opportunities and challenges in the market and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micromarkets with respect to their individual growth trends and forecasts the revenue of the market segments with respect to five main regions.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to position their businesses better and make suitable go-to-market strategies. This report will enable stakeholders to understand the pulse of the market and provide them with information on the key market drivers, restraints, opportunities, and challenges.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 OBJECTIVES OF THE STUDY
  • 1.2 MARKET DEFINITION
  • 1.3 MARKET SCOPE
    • 1.3.1 MARKETS COVERED
    • 1.3.2 YEARS CONSIDERED FOR THE STUDY
  • 1.4 CURRENCY USED FOR THE STUDY
  • 1.5 MAJOR MARKET STAKEHOLDERS

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
    • 2.1.1 SECONDARY DATA
      • 2.1.1.1 Secondary sources
    • 2.1.2 PRIMARY DATA
  • 2.2 MARKET ESTIMATION METHODOLOGY
    • 2.2.1 REVENUE MAPPING-BASED MARKET ESTIMATION
    • 2.2.2 PROCEDURE-BASED MARKET ESTIMATION
    • 2.2.3 PRIMARY RESEARCH VALIDATION
  • 2.3 DATA TRIANGULATION
  • 2.4 RESEARCH ASSUMPTIONS
  • 2.5 RESEARCH LIMITATIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

  • 4.1 HLA TYPING MARKET: MARKET OVERVIEW
  • 4.2 GLOBAL MARKET BREAKDOWN, BY PRODUCT & SERVICE
  • 4.3 HLA TYPING MARKET, BY TECHNOLOGY
  • 4.4 HLA TYPING MARKET, BY APPLICATION
  • 4.5 HLA TYPING MARKET, BY END USER
  • 4.6 GEOGRAPHIC SNAPSHOT OF THE HLA TYPING MARKET

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • 5.2.1 DRIVERS
      • 5.2.1.1 Increasing number of organ transplantation procedures
      • 5.2.1.2 Technological advancements in the field of HLA typing
      • 5.2.1.3 Increasing public-private funding for research
      • 5.2.1.4 Increasing prevalence of infectious & non-infectious diseases
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 High cost of HLA typing products
      • 5.2.2.2 Limited reimbursements for target procedures
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Rising adoption of cross-matching and chimerism testing
      • 5.2.3.2 Increasing public awareness about transplantation
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Supply-demand gap between the number of organ donors and organs required annually
      • 5.2.4.2 Dearth of skilled professionals for performing HLA typing

6 HLA TYPING MARKET, BY PRODUCT & SERVICE

  • 6.1 INTRODUCTION
  • 6.2 REAGENTS & CONSUMABLES
    • 6.2.1 EXPANDING APPLICATIONS OF MOLECULAR ASSAY TECHNIQUES LIKE PCR AND NGS IN HLA TYPING WILL AID MARKET GROWTH
  • 6.3 INSTRUMENTS
    • 6.3.1 TECHNOLOGICAL ADVANCEMENTS AND INCREASING AWARENESS SUPPORT THE ADOPTION OF INSTRUMENTS
  • 6.4 SOFTWARE & SERVICES
    • 6.4.1 AUTOMATION AND DIGITIZATION IN LAB PROCEDURES AND RISING DEMAND FOR SPECIALIZED EQUIPMENT ARE DRIVING MARKET GROWTH

7 HLA TYPING MARKET, BY TECHNOLOGY

  • 7.1 INTRODUCTION
  • 7.2 MOLECULAR ASSAY TECHNOLOGIES
    • 7.2.1 PCR-BASED MOLECULAR ASSAYS
      • 7.2.1.1 Sequence-specific primer-PCR
        • 7.2.1.1.1 Expanding distribution networks of key PCR manufacturers to support market growth
      • 7.2.1.2 Sequence-specific oligonucleotide-PCR
        • 7.2.1.2.1 High demand of SSO-PCR is due to its benefits in donor-recipient cross-matching and disease diagnosis
      • 7.2.1.3 Real-time PCR
        • 7.2.1.3.1 Growing end-user preference for genome-based molecular diagnostics has supported the demand for real-time PCR
      • 7.2.1.4 Other PCR-based molecular assays
    • 7.2.2 SEQUENCING-BASED MOLECULAR ASSAYS
      • 7.2.2.1 Sanger sequencing
        • 7.2.2.1.1 Rising end-user preference for low-cost and efficient DNA sequencing technology drives market growth
      • 7.2.2.2 Next-generation sequencing
        • 7.2.2.2.1 High scalability, low turnaround time, and high-throughput capabilities have fueled the use of NGS
      • 7.2.2.3 Other sequencing-based molecular assays
  • 7.3 NON-MOLECULAR ASSAY TECHNOLOGIES
    • 7.3.1 RAPID ADOPTION OF MOLECULAR ASSAY TECHNIQUES WILL HAMPER MARKET GROWTH IN THIS SEGMENT

8 HLA TYPING MARKET, BY APPLICATION

  • 8.1 INTRODUCTION
  • 8.2 DIAGNOSTIC APPLICATIONS
    • 8.2.1 DONOR-RECIPIENT CROSS-MATCHING
      • 8.2.1.1 Need for histocompatibility cross-matching in organ transplantation drives market growth
    • 8.2.2 INFECTIOUS DISEASE TESTING
      • 8.2.2.1 Growing burden of infectious diseases is likely to aid market growth
    • 8.2.3 CANCER DIAGNOSIS & PREVENTION
      • 8.2.3.1 Clinical evidence for the success of HLA typing in cancer diagnostics will positively affect this market
    • 8.2.4 TRANSFUSION THERAPY
      • 8.2.4.1 Increasing evidence for the success of HLA typing in blood transfusion is a key contributor to market growth
    • 8.2.5 OTHER DIAGNOSTIC APPLICATIONS
  • 8.3 RESEARCH APPLICATIONS
    • 8.3.1 RISING FUNDING FOR RESEARCH AND EXPANDING APPLICATIONS OF HLA TYPING ARE DRIVING MARKET GROWTH

9 HLA TYPING MARKET, BY END USER

  • 9.1 INTRODUCTION
  • 9.2 COMMERCIAL SERVICE PROVIDERS
    • 9.2.1 RAPID MODERNIZATION AND AUTOMATION IN HLA TYPING TO SUPPORT MARKET GROWTH IN THIS SEGMENT
  • 9.3 HOSPITALS & TRANSPLANT CENTERS
    • 9.3.1 HIGH PURCHASING POWER OF HOSPITALS HAS ENSURED STRONG ADOPTION OF INSTRUMENTS, REAGENTS, AND CONSUMABLES
  • 9.4 RESEARCH LABORATORIES & ACADEMIC INSTITUTES
    • 9.4.1 RISING GOVERNMENT SUPPORT FOR RESEARCH RELATED TO CANCER DIAGNOSIS WILL PROPEL MARKET GROWTH

10 HLA TYPING MARKET, BY REGION

  • 10.1 INTRODUCTION
  • 10.2 NORTH AMERICA
    • 10.2.1 US
      • 10.2.1.1 Technological advancements in the field of HLA typing will drive market growth in the US
    • 10.2.2 CANADA
      • 10.2.2.1 Rising incidence of cancer will support the adoption of genomic research in Canada
  • 10.3 EUROPE
    • 10.3.1 GERMANY
      • 10.3.1.1 Germany accounted for the largest share of the European market
    • 10.3.2 UK
      • 10.3.2.1 Rising prevalence of autoimmune diseases drives market growth in the UK
    • 10.3.3 FRANCE
      • 10.3.3.1 Increasing organ rejection rate drives the need for HLA typing in France
    • 10.3.4 ITALY
      • 10.3.4.1 Italy's healthcare sector has witnessed sluggish growth in recent years
    • 10.3.5 SPAIN
      • 10.3.5.1 Rising number of solid-organ transplantation procedures to drive market growth in Spain
    • 10.3.6 REST OF EUROPE
  • 10.4 ASIA PACIFIC
    • 10.4.1 CHINA
      • 10.4.1.1 Supportive government regulations will drive market growth in China
    • 10.4.2 INDIA
      • 10.4.2.1 Increasing number of transplantation procedures drives market growth in India
    • 10.4.3 JAPAN
      • 10.4.3.1 Limited research and exploration in the diagnostics field to limit the adoption of HLA procedures
    • 10.4.4 AUSTRALIA
      • 10.4.4.1 Rising prevalence of coeliac disease in Australia to support the HLA typing market
    • 10.4.5 SOUTH KOREA
      • 10.4.5.1 Expansion by leading market players in South Korea will support market growth
    • 10.4.6 REST OF ASIA PACIFIC
  • 10.5 LATIN AMERICA
    • 10.5.1 BRAZIL
      • 10.5.1.1 Brazil dominates the LATAM market
    • 10.5.2 MEXICO
      • 10.5.2.1 Rising medical tourism to support market growth in Mexico
    • 10.5.3 REST OF LATAM
  • 10.6 MIDDLE EAST AND AFRICA
    • 10.6.1 MEA WILL HOLD A SMALLER SHARE AND GROW AT A LESSER RATE THAN MAJOR REGIONAL MARKETS

11 COMPETITIVE LANDSCAPE

  • 11.1 OVERVIEW
  • 11.2 MARKET SHARE ANALYSIS
  • 11.3 COMPETITIVE SCENARIO
    • 11.3.1 KEY PRODUCT LAUNCHES AND APPROVALS
    • 11.3.2 KEY AGREEMENTS AND COLLABORATIONS
    • 11.3.3 KEY ACQUISITIONS
    • 11.3.4 KEY EXPANSIONS
  • 11.4 COMPETITIVE LEADERSHIP MAPPING
    • 11.4.1 VISIONARY LEADERS
    • 11.4.2 INNOVATORS
    • 11.4.3 DYNAMIC DIFFERENTIATORS
    • 11.4.4 EMERGING COMPANIES

12 COMPANY PROFILES

(Business Overview, Products Offered, Recent Developments, MnM View)*

  • 12.1 THERMO FISHER SCIENTIFIC
  • 12.2 QIAGEN
  • 12.3 ILLUMINA
  • 12.4 F. HOFFMAN-LA ROCHE LIMITED
  • 12.5 BIO-RAD LABORATORIES
  • 12.6 BECTON, DICKINSON AND COMPANY
  • 12.7 TBG DIAGNOSTICS
  • 12.8 FUJIREBIO
  • 12.9 TAKARA BIO
  • 12.10 CAREDX
  • 12.11 OMIXON
  • 12.12 IMMUCOR
  • 12.13 GENOME DIAGNOSTICS
  • 12.14 BIOFORTUNA
  • 12.15 CREATIVE BIOLABS
  • 12.16 OTHER COMPANIES
    • 12.16.1 BAG HEALTHCARE
    • 12.16.2 HISTOGENETICS
    • 12.16.3 PACIFIC BIOSCIENCES OF CALIFORNIA
    • 12.16.4 BGI GENOMICS
    • 12.16.5 KRISHGEN BIOSYSTEMS

Business Overview, Products Offered, Recent Developments, MnM View might not be captured in case of unlisted companies.

13 APPENDIX

  • 13.1 DISCUSSION GUIDE
  • 13.2 KNOWLEDGE STORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 13.3 AVAILABLE CUSTOMIZATIONS
  • 13.4 RELATED REPORTS
  • 13.5 AUTHOR DETAILS